Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy

Open access
Kline, Cassie N., Joseph, Nancy M., Grenert, James P., van Ziffle, Jessica, Talevich, Eric, Onodera, Courtney, Aboian, Mariam, Cha, Soonmee, Raleigh, David R., Braunstein, Steve, Torkildson, Joseph, Samuel, David, Bloomer, Michelle, Campomanes, Alejandra G. de Alba, Banerjee, Anuradha, Butowski, Nicholas, Raffel, Corey, Tihan, Tarik, Bollen, Andrew W., Phillips, Joanna J., Korn, W. Michael, Yeh, Iwei, Bastian, Boris C., Gupta, Nalin, Mueller, Sabine, Perry, Arie, Nicolaides, Theodore, Solomon, David A. · 2016 · Neuro-Oncology

Abstract

Background: Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neuro-oncology patients. Methods: We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes. Results: Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor. In 25 cases (81%), results impacted patient management by: (i) clarifying diagnosis, (ii) identifying pathogenic germline mutations, or (iii) detecting potentially targetable alterations. The pathologic diagnosis was amended after genomic profiling for 6 patients (19%), including a high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to CNS high-grade neuroepithelial tumor with BCOR alteration. Multiple patients had pathogenic germline mutations, many of which were previously unsuspected. Potentially targetable alterations were identified in 19 patients (61%). Additionally, novel likely pathogenic alterations were identified in 3 cases: an in-frame RAF1 fusion in a BRAF wild-type pleomorphic xanthoastrocytoma, an inactivating ASXL1 mutation in a histone H3 wild-type diffuse pontine glioma, and an in-frame deletion within exon 2 of MAP2K1 in a low-grade astrocytic neoplasm. Conclusions: Our experience demonstrates the significant impact of molecular profiling on diagnosis and treatment of pediatric brain tumors and confirms its feasibility for use at the time of diagnosis or recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/now254

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Kline, C. N., Joseph, N. M., Grenert, J. P., van Ziffle, J., Talevich, E., Onodera, C., Aboian, M., Cha, S., Raleigh, D. R., Braunstein, S., Torkildson, J., Samuel, D., Bloomer, M., Campomanes, A. G. D. A., Banerjee, A., Butowski, N., Raffel, C., Tihan, T., Bollen, A. W., Phillips, J. J., Korn, W. M., Yeh, I., Bastian, B. C., Gupta, N., Mueller, S., Perry, A., Nicolaides, T., & Solomon, D. A.
Venue
Neuro-Oncology
Published
2016-11-14
Volume
19
Issue
5
Pages
now254
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2555272704
Cited by
228
References
4
FWCI
16.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.